Research programme: fibroblast growth factor receptor-3 antibodies - Progenika BiopharmaAlternative Names: Research programme: bladder cancer - Progenika Biopharma; Research programme: FGFR3 antibodies - Progenika Biopharma
Latest Information Update: 23 Jan 2017
At a glance
- Originator Progenika Biopharma
- Class Monoclonal antibodies
- Mechanism of Action Fibroblast growth factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bladder cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bladder-cancer in Spain
- 22 Mar 2006 Preclinical trials in Bladder cancer in Spain (unspecified route)